Telavancin: A lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults

Clinical Therapeutics

Volumn 32, Issue 13, 2010, Pages 2160-2185

  Chang, Mei H ^a   Kish, Troy D ^b   Fung, Horatio B ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

Author keywords

Complicated skin and skin structure infection; Glycopeptides; Lipoglycopeptide; Telavancin

Indexed keywords

AZTREONAM; CLOXACILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; MIDAZOLAM; NAFCILLIN; OXACILLIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; ANXIETY; ARTICLE; CHILL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE INFECTION; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INSOMNIA; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; SKIN INFECTION; SKIN STRUCTURE; SYSTEMATIC REVIEW; TASTE DISORDER; URINE COMPOSITION DISORDER; VOMITING;

ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; SKIN DISEASES, INFECTIOUS;

EID: 79951528243     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(11)00020-8     Document Type: Article

References (106)

1. Rammelkamp CH, Maxon T Resistance of Staphylococcus aureus to the action of penicillin. Proc Royal Soc Exper Biol Med. 1942, 51:386-389.
2. Barber M Staphylococcal infection due to penicillinresistant strains. Br Med J. 1947, 2:863-865.
3. Munch-Petersen E, Boundy C Yearly incidence ofpenicillinresistant staphylococci in man since 1942. Bull World Health Organ. 1962, 26:241-252.
4. "Celbemom"-resistant staphylococci. Br Med J. 1961, 1:113-114.
5. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillinresistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol. 1992, 13:582-586.
6. Styers D, Sheehan DJ, Hogan P, Sahm DF Laboratorybased surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 Status in the United States. Ann Clin Microbiol Antimicrob. 2006, 5:2.
7. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 [published correction appears in Infect Control Hosp Epidemiol. 2009;30:107]. Infect Control Hosp Epidemiol. 2008, 29:996-1011. National Healthcare Safety Network Team, Participating National Healthcare Safety Network Facilities.
8. Rosenthal VD, Maki DG, Jamulitrat S, et al. International Nosocomial Infection Control Consortium (INCC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control. 2010, 38:95-104.e2. INICC Members.
9. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant, S. aureus infections among patients in the emergency department. N Engl J Med. 2006, 355:666-674. EMERGEncy ID Net Study Group.
10. Weber JT Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2005, 41(Suppl 4):S269-S272.
11. David MZ, Mennella C, Mansour M, et al. Predominance of methicillinresistant Staphylococcus aureus among pathogens causing skin and soft tissue infections in a large urban jail: Risk factors and recurrence rates. J Clin Microbiol. 2008, 46:3222-3227.
12. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG Vancomycin-associated nephrotoxicity: Grave concern or death by character assassination?. Am J Med. 2010, 123:182.e1-182.e7.
13. Pallares R, Dick R, Wenzel RP, et al. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infect Control Hosp Epidemiol. 1993, 14:376-382.
14. Vancomycin hydrochloride [package insert] 2008, Baxter Healthcare Corporation, Deerfield, Ill, Accessed April 28, 2010. http://www.vancocin.com/~/media/Vancocin/Files/Vancocin_PI.ashx.
15. Tenover FC, Moellering RC The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007, 44:1208-1215.
16. Steinkraus G, White R, Friedrich L Vancomycin MIC creep in nonvancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007, 60:788-794.
17. Maor Y, Hagin M, Belausov N, et al. Clinical features of heteroresistant vancomycin-intermediate Staphylo-coccus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis. 2009, 199:619-624.
18. Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis. 2008, 46:668-674.
19. Finks J, Wells E, Dyke TL, et al. Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007. Emerg Infect Dis. 2009, 15:943-945.
20. Vibativ [package insert] 2009, Theravance Inc, South San Francisco, Calif, Accessed April 28, 2010. http://www.astellas.us/docs/us/VIBATIV_PI_Final.pdf.
21. Van Bambeke F Glycopeptides in clinical development: Pharmacological profile and clinical perspectives. Curr Opin Pharmacol. 2004, 4:471-478.
22. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005, 49:1127-1134.
23. Courvalin P Dual mode of action of telavancin against Staphylococcus aureus. Abstract presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases April 19-22, 2008, Abstract S415.
24. Benton B, Breukink E, Visscher I, et al. Telavancin inhibits peptidoglycan biosynthesis through preferential targeting of transglycosylation: Evidence for multivalent interaction between telavancin and lipid II. Abstract presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases March 31-April 4, 2007, Abstract 160.
25. Lunde CS, Hartouni SR, Janc JW, et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother. 2009, 53:3375-3383.
26. Lunde CS, Rexer CH, Hartouni SR, et al. Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus. Antimicrob Agents Chemother. 2010, 54:2198-2200.
27. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, et al. Evaluation of the extracellular and intra-cellular activities (human THP-1 mac-rophages) of telavancin versus vancomycin against methicillin-susceptible, methicillinresistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006, 58:1177-1184.
28. Fritsche TR, Sader HS, Jones RN Antimicrobial activity of telavancin tested against contemporary grampositive pathogens: Results from an international surveillance program (2007). Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/ 46th Annual Meeting of the Infectious Diseases Society of America October 25-28, 2008, Abstract C1-148.
29. Draghi DC, Benton BM, Krause KM, et al. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother. 2008, 52:2383-2388.
30. Draghi DC, Benton BM, Krause KM, et al. In vitro activity of telavancin against recent gram-positive clinical isolates: Results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother. 2008, 62:116-121.
31. Nichol KA, Weshnoweski B, Vashisht R, et al. Activity of telavancin against gram-positive cocci isolated from Canadian hospitals: CANWARD 2007. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America October 25-28, 2008, Abstract C1-150.
32. Sader H, Rhomberg P, Jones R Telavancin activity against S. aureus and coagulase-negative staphylococci collected from clinical infections in Europe (2007-2008). Abstract presented at: 19th European Congress of Clinical Microbiology and Infectious Diseases May 16-19, 2009, Abstract P1846.
33. Mendes RE, Sader HS, Jones RN Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008). Int J Antimicrob Agents. 2010, 36:374-379.
34. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard-Eighth Edition 2007, Clinical and Laboratory Standards Institute, CLSI, Wayne, Pa, Publication no. M07-A8.
35. King A, Phillips I, Kaniga K Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother. 2004, 53:797-803.
36. Jansen WT, Verel A, Verhoef AV, Milatovic D In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother. 2007, 51:3420-3424.
37. Sahm D, Draghi D, Benton B, et al. Europe surveillance initiative profiling the anti-enterococcal activity of telavancin by specimen source from 2004 to 2005. Abstract presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases March 31-April 4, 2007, Abstract 324.
38. Jones R, Rhomberg P, Sader H Telavancin antimicrobial activity when tested against enterococci and uncommonly isolated gram-positive species (European sample for 2007-2008). Abstract presented at: 19th European Congress of Clinical Microbiology and Infectious Diseases May 16-19, 2009, Abstract P1848.
39. Finegold SM, Bolanos M, Sumannen PH, Molitoris DR In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates. Antimicrob Agents Chemother. 2009, 53:3996-4001.
40. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of the new semisynthetic glycopeptides telavancin (TD-6424), vancomycin, daptomycin, linezolid and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother. 2004, 48:2149-2152.
41. Saravolatz LD, Pawlak J, Johnson LB Comparative activity of telavancin against isolates of communityassociated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2007, 60:406-409.
42. Krause KM, Renelli M, Difuntorum S, et al. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother. 2008, 52:2647-2652.
43. LaPlante KL, Mermel LA In vitro activity of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis and Enterococcus faecalis strains. Antimicrob Agents Chemother. 2009, 53:3166-3169.
44. Gander S, Kinnaird A, Finch R Telavancin: In vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother. 2005, 56:337-343.
45. Smith K, Gemmell CG, Lang S A comparison of model systems for the evaluation of telavancin and vancomycin susceptibility testing of Staphylococcus aureus biofilms. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy September 12-15, 2009, Abstract A1-1291.
46. Leuthner KD, Cheung CM, Rybak MJ Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide nonsusceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006, 58:338-343.
47. Pankuch GA, Appelbaum PC In vitro activity of telavancin and other antimicrobial agents against vancomycin susceptible and non-susceptible MRSA. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America October 25-28, 2008, Abstract C1-191.
48. Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005, 49:195-201.
49. Gotfried MH, Shaw JP, Benton BM, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008, 52:92-97.
50. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006, 50:862-867. FAST 2 Investigator Group.
51. Lodise TP, Gotfried M, Barriere S, Drusano GL Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2008, 52:2300-2304.
52. Sun HK, Duchin K, Nightingale CH, et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother. 2006, 50:788-790.
53. Shaw JP, McCullough J, Tsai SJ Protein binding of [14C]-telavancin in plasma and human skin blister fluid. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America October 25-28, 2008, Abstract A-1878.
54. Shaw JP, Goldberg MR, Cheong J, Kitt MM Pharmacokinetics, excretion, and mass balance of telavancin following intravenous administration of [14C]-telavancin to healthy subjects. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America October 25-28, 2008, Abstract A-1879.
55. Wong SL, Barriere SL, Kitt MM, Goldberg MR Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother. 2008, 62:780-783.
56. Duchin K Single dose pharmacokinetics of telavancin in subjects with renal dysfunction. Abstract presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases May 1-4, 2004, Abstract P-1028.
57. Duchin K, Shaw J, Seroogy J, et al. Effect of haemodialysis on single dose pharmacokinetics of telavancin. Abstract presented at: 15th European Congress of Clinical Microbiology and Infectious Diseases April 2-5, 2005, Abstract 96.
58. Duchin K Single dose pharmacokinetic of telavancin in healthy elderly subjects. Abstract presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases May 1-4, 2004, Abstract P-1027.
59. Goldberg MR, Wong SL, Shaw JP, et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy. 2010, 30:35-42.
60. Odenholt I, Löwdin E, Cars O Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model. Antimicrob Agents Chemother. 2007, 51:3311-3316.
61. Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother. 2003, 47:3602-3604.
62. Pankuch GA, Appelbaum PC Postantibiotic effects of telavancin against 16 gram-positive organisms. Antimicrob Agents Chemother. 2009, 53:1275-1277.
63. Hegde SS, Reyes N, Weins T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent against gram-positive bacteria. Antimicrob Agents Chemother. 2004, 48:3043-3050.
64. Leonard SN, Vidaillac C, Rybak MJ Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2009, 53:2928-2933.
65. Lin G, Pankuch GA, Ednie LM, Appelbaum PC Antistaphylococcal activity of telavancin tested alone and in combination by time-kill assay. Antimicrob Agents Chemother. 2010, 54:2201-2205.
66. Bowker KE, Noel AR, Tomaselli SG, MacGowan AP Pharmacodynamics of telavancin: Relationship of AUC/ MIC of antibacterial effect and emergence of resistance. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America October 25-28, 2008, Abstract A-980.
67. Kosowska-Shick K, Clark C, Pankuch GA, et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob Agents Chemother. 2009, 53:4217-4224.
68. Krause KM, Benton BM, Higgins DL, et al. Telavancin possesses low potential for resistant mutant selection in serial passage studies of Staphylococcus aureus and enterococci. Abstract presented at: 15th European Congress of Clinical Microbiology and Infectious Diseases April 2-5, 2005, Abstract 346.
69. Reyes N, Skinner R, Benton BM, et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006, 58:462-465.
70. Hegde SS, Skinner R, Lewis SR, et al. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. J Antimicrob Chemother. 2010, 65:725-728.
71. Hegde S, Skinner R, Reyes N, et al. Efficacy of telavancin in a murine model of bacteremia caused by a strain of vancomycin-resistant Enterococcus faecalis. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy September 12-15, 2009, Abstract B-1321.
72. Hegde SS, Reyes N, Skinner R, Difuntorum S Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother. 2008, 61:169-172.
73. Reyes N, Skinner R, Kaniga K, et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanism of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005, 49:4344-4346.
74. Yin LY, Calhoun JH, Thomas TS, Wirtz ED Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: Studies with a rabbit model. J Antimicrob Chemother. 2009, 63:357-360.
75. Hatano K, Wakai Y, Takeda S, Maki K Efficacy of telavancin in a murine model of acute suppurative osteomyelitis induced by methicillinresistant Staphylococcus aureus. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America October 25-28, 2008, Abstract B-1002.
76. Miró JM, Garcia-de-la-Mària C, Armero Y, et al. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2007, 51:2373-2377. Hospital Clinic Experimental Endocarditis Study Group.
77. Madrigal AG, Basuino L, Chambers HF Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycinintermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2005, 49:3163-3165.
78. Stucki A, Gerber P, Acosta F, et al. Efficacy of telavancin against penicillinresistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother. 2006, 50:770-773.
79. Darouiche RO, Mansouri MD, Schneidkraut MJ Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits. Antimicrob Agents Chemother. 2009, 53:2626-2628.
80. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005, 40:1601-1607. FAST Investigator Group.
81. Corey GR, Stryjewski ME, O'Riordan WD, et al. ATLAS 1: The first Phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections. Abstract presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases March 31-April 4, 2007, ATLAS Study Group, Abstract 343.
82. Corey GR, Stryjewski ME, Fowler VG, et al. ATLAS 2: A double-blind, randomized, active controlled, multinational Phase 3 study comparing telavancin with vancomycin for the treatment of patients with complicated skin and skin structure infections. Abstract presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases March 31-April 4, 2007, ATLAS Study Group, Abstract 344.
83. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008, 46:1683-1693. Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study.
84. Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for hospitalacquired pneumonia including ventilator-associated pneumonia: The ATTAIN studies. Abstract presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases April 19-22, 2008, Abstract O75.
85. Telavancin (TD 6424, ArbelicTM) for the treatment of uncomplicated Staphylococcus aureus bacteremia Accessed April 28, 2010. http://clinicaltrials.gov/ct2/showNCT00062647?term=telavancin&rank=1.
86. Aguiar MW Theravance announces FDA acceptance of telavancin NDA for the treatment of hospital-acquired pneumonia (Theravance, Inc., South San Francisco, Calif), Accessed April 28, 2010. http://investor.theravance.com/releasedetail.cfm?ReleaseID=375774.
87. Berrie C Telavancin shows benefits for treatment of hospital-acquired pneumonia: Presented at ECCMID Accessed April 28, 2010. http://www.docguide.com/dg.nsf/PrintPrint/5DFFBFA9EE8BF19985257432007BBF02.
88. Rubinstein E, Corey GR, Boucher HW, et al. Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: The ATTAIN studies. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America October 25-28, 2008, ATTAIN Study Group, Abstract K-529.
89. Corey GR, Rubinstein E, Lalani T, et al. Telavancin for hospitalacquired pneumonia caused by S. aureus: Efficacy analysis according to the in vitro susceptibility to vancomycin. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America October 25-28, 2008, ATTAIN Study Group, Abstract K-528.
90. Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for treatment of hospital-acquired pneumonia caused by MRSA and MSSA: The ATTAIN studies. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America October 25-28, 2008, ATTAIN Study Group, Abstract K-530.
91. Medical review (Part 1), Vibativ (telavancin) injection drug approval package (Application number: 22-110). Center for Drug Evaluation and Research, US Food and Drug Administration Accessed April 28, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022110s000_MedR_P1.pdf.
92. Barriere S, Genter F, Spencer E, et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004, 44:689-695.
93. Risk evaluation and mitigation strategy, Vibativ (telavancin) injection. US Food and Drug Administration September 11, 2009, Accessed April 28, 2010. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/UCM187534.
94. Wong SL, Goldberg MR, Ballow CH, et al. Effect of telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: A randomized, doubleblind, crossover study in healthy subjects. Pharmacotherapy. 2010, 30:136-143.
95. Wong SL, Sörgel F, Kinzig M, et al. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. J Clin Pharmacol. 2009, 49:816-823.
96. Goldberg MR, Wong SL, Shaw JP, et al. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy. 2010, 30:806-811.
97. Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008, 28:1471-1482.
98. Gilbert DN, Moellering RC, Eliopoulos GM, et al. The Sanford Guide to Antimicrobial Therapy 2010, Antimicrobial Therapy Inc, Sperryville, Va. 40th ed.
99. Vancomycin [package insert] 2008, Hospira, Inc, Lake Forest, Ill.
100. Cubicin (daptomycin) [package insert] 2008, Cubists Pharmaceuticals, Inc, Lexington, Mass.
101. Zyvox (linezolid) [package insert] 2010, Pharmacia & Upjohn Company, Division of Pfizer Inc, New York, NY.
102. Synercid (quinupristin/dalfopristin) [package insert] 2007, DSM Pharmaceuticals, Inc, Greenville, NC.
103. Tygacil (tigecycline) [package insert] 2010, Wyeth Pharmaceuticals, Inc, Philadelphia, Pa.
104. Doan TL, Fung HB, Mehta D, Riska PF Tigecycline: A glycylcycline antimicrobial agent. Clin Ther. 2006, 28:1079-1106.
105. 2010 Drug Topics Red Book 2010, Thomson Medical Economics, Montvale, NJ.
106. Approval letter, Vibativ (telavancin) injection drug approval package (Application number: 22-110). Center for Drug Evaluation and Research, US Food and Drug Administration Accessed April 28, 2010. http://www.accessdata.fda.gov/drugsatfda_docsnda/2009/022110s000_Approv.pdf.